Theragen Etex Co.Ltd - Asset Resilience Ratio
Theragen Etex Co.Ltd (066700) has an Asset Resilience Ratio of 0.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 066700 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Theragen Etex Co.Ltd's Asset Resilience Ratio has changed over time. See Theragen Etex Co.Ltd (066700) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Theragen Etex Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 066700 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.72 Billion | 0.68% |
| Total Liquid Assets | ₩1.72 Billion | 0.68% |
Asset Resilience Insights
- Limited Liquidity: Theragen Etex Co.Ltd maintains only 0.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Theragen Etex Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Theragen Etex Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 65.38% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
Annual Asset Resilience Ratio for Theragen Etex Co.Ltd (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Theragen Etex Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.04% | ₩2.67 Billion ≈ $1.81 Million |
₩257.63 Billion ≈ $174.59 Million |
+0.20pp |
| 2024-12-31 | 0.83% | ₩1.98 Billion ≈ $1.34 Million |
₩237.00 Billion ≈ $160.61 Million |
+0.20pp |
| 2023-12-31 | 0.64% | ₩1.55 Billion ≈ $1.05 Million |
₩243.14 Billion ≈ $164.77 Million |
-8.03pp |
| 2022-12-31 | 8.66% | ₩21.36 Billion ≈ $14.48 Million |
₩246.55 Billion ≈ $167.09 Million |
+4.79pp |
| 2021-12-31 | 3.88% | ₩13.57 Billion ≈ $9.20 Million |
₩350.07 Billion ≈ $237.24 Million |
+0.93pp |
| 2020-12-31 | 2.95% | ₩15.77 Billion ≈ $10.68 Million |
₩534.89 Billion ≈ $362.48 Million |
-1.60pp |
| 2019-12-31 | 4.55% | ₩10.98 Billion ≈ $7.44 Million |
₩241.50 Billion ≈ $163.66 Million |
-4.73pp |
| 2018-12-31 | 9.28% | ₩16.21 Billion ≈ $10.99 Million |
₩174.68 Billion ≈ $118.38 Million |
+4.25pp |
| 2017-12-31 | 5.03% | ₩7.31 Billion ≈ $4.96 Million |
₩145.42 Billion ≈ $98.55 Million |
-0.75pp |
| 2016-12-31 | 5.78% | ₩8.14 Billion ≈ $5.52 Million |
₩140.96 Billion ≈ $95.52 Million |
+1.35pp |
| 2015-12-31 | 4.43% | ₩6.10 Billion ≈ $4.14 Million |
₩137.93 Billion ≈ $93.47 Million |
-5.63pp |
| 2014-12-31 | 10.05% | ₩12.64 Billion ≈ $8.56 Million |
₩125.69 Billion ≈ $85.18 Million |
+1.96pp |
| 2013-12-31 | 8.09% | ₩9.79 Billion ≈ $6.63 Million |
₩120.96 Billion ≈ $81.97 Million |
+4.69pp |
| 2012-12-31 | 3.40% | ₩3.87 Billion ≈ $2.62 Million |
₩113.82 Billion ≈ $77.14 Million |
-0.89pp |
| 2011-12-31 | 4.29% | ₩4.29 Billion ≈ $2.91 Million |
₩100.16 Billion ≈ $67.88 Million |
-0.50pp |
| 2010-12-31 | 4.79% | ₩4.69 Billion ≈ $3.18 Million |
₩98.05 Billion ≈ $66.45 Million |
-10.95pp |
| 2009-12-31 | 15.73% | ₩13.89 Billion ≈ $9.42 Million |
₩88.30 Billion ≈ $59.84 Million |
+11.58pp |
| 2008-12-31 | 4.16% | ₩3.07 Billion ≈ $2.08 Million |
₩73.91 Billion ≈ $50.08 Million |
+0.91pp |
| 2007-12-31 | 3.24% | ₩1.72 Billion ≈ $1.16 Million |
₩52.89 Billion ≈ $35.84 Million |
+0.32pp |
| 2006-12-31 | 2.93% | ₩1.25 Billion ≈ $845.38K |
₩42.65 Billion ≈ $28.90 Million |
+0.77pp |
| 2005-12-31 | 2.16% | ₩988.32 Million ≈ $669.77K |
₩45.79 Billion ≈ $31.03 Million |
-- |
About Theragen Etex Co.Ltd
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company wa… Read more